ArticleClinical ophthalmology (Auckland, N.Z.)2014
The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women.
Article in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Ellipsoid Zone Hyporeflectivity as an Early Sign of Non-Reversible Hydroxychloroquine Retinopathy: A Case Series.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.Current ophthalmology reports · 2024Article
- Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.Nature reviews. Rheumatology · 2018Review
- Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.Arthritis research & therapy · 2018Article
- Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.Clinical rheumatology · 2018Article
- Solving the Hydroxychloroquine Dosing Dilemma With a Smartphone App.JAMA ophthalmology · 2018Article
- Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Hydroxychloroquine retinopathy.Eye (London, England) · 2017Review
- Effect of Hydroxychloroquine on the Retinal Layers: A Quantitative Evaluation with Spectral-Domain Optical Coherence Tomography.Journal of ophthalmology · 2016Article
- Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2015Article
- Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine how algorithms for ideal body weight (IBW) affect hydroxychloroquine dosing in women.
methodsThis was a retrospective study of 520 patients screened for hydroxychloroquine retinopathy. Charts were reviewed for sex, height, weight, and daily dose. The outcome measures were ranges of IBW across algorithms; rates of potentially toxic dosing; height thresholds below which 400 mg/d dosing is potentially toxic; and rates for which actual body weight (ABW) was less than IBW.
resultsWomen made up 474 (91%) of the patients. The IBWs for a height varied from 30-34 pounds (13.6-15.5 kg) across algorithms. The threshold heights below which toxic dosing occurred varied from 62-70 inches (157.5-177.8 cm). Different algorithms placed 16%-98% of women in the toxic dosing range. The proportion for whom dosing should have been based on ABW rather than IBW ranged from 5%-31% across algorithms.
conclusionAlthough hydroxychloroquine dosing should be based on the lesser of ABW and IBW, there is no consensus about the definition of IBW. The Michaelides algorithm is associated with the most frequent need to adjust dosing; the Metropolitan Life Insurance, large frame, mean value table with the least frequent need. No evidence indicates that one algorithm is superior to others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.